Company earnings

ALMS Earnings Date & History

Alumis Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Aug 19, 2026 at 4:07 PM ET

Alumis Inc

Pharmaceuticals

Next earnings date
Wednesday, August 19, 2026
Reporting session
Time TBD
EPS estimate
$-0.74
Revenue estimate
$3.5M

ALMS earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Thursday, May 14, 2026Q1 2026$-0.78$-0.74+4.7%$1.7M
Thursday, March 19, 2026Q4 2025$-1.00$-0.94+5.8%$1.9M
Thursday, November 13, 2025Q3 2025$-0.93$-1.06-13.4%$2.1M
Wednesday, August 13, 2025Q2 2025$-1.41$-1.68-19.6%$2.7M

What the market is watching in ALMS's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only — not investment advice.

Frequently asked questions

When is the next ALMS earnings date?
Alumis Inc is scheduled to report on Wednesday, August 19, 2026 (Time TBD). Dates can change until the company confirms them.
Does ALMS report before or after the market?
The next report is scheduled time tbd.
What EPS is expected for ALMS?
Consensus EPS for the upcoming quarter is $-0.74, on revenue of $3.5M.

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

ALMS earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.